Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures
Weiyan Cheng, Zhiheng Yang, Suhua Wang, et al.
European Journal of Medicinal Chemistry (2019) Vol. 164, pp. 615-639
Closed Access | Times Cited: 87

Showing 1-25 of 87 citing articles:

Development of selective mono or dual PROTAC degrader probe of CDK isoforms
Fei Zhou, Luyu Chen, Chao-Guo Cao, et al.
European Journal of Medicinal Chemistry (2019) Vol. 187, pp. 111952-111952
Closed Access | Times Cited: 92
Discovery of novel pyrimidine-based benzothiazole derivatives as potent cyclin-dependent kinase 2 inhibitors with anticancer activity
Peng-Cheng Diao, Wei-Yuan Lin, Xie‐Er Jian, et al.
European Journal of Medicinal Chemistry (2019) Vol. 179, pp. 196-207
Closed Access | Times Cited: 86
3-Hydrazinoisatin-based benzenesulfonamides as novel carbonic anhydrase inhibitors endowed with anticancer activity: Synthesis, in vitro biological evaluation and in silico insights
Mahmoud F. Abo-Ashour, Wagdy M. Eldehna, Alessio Nocentini, et al.
European Journal of Medicinal Chemistry (2019) Vol. 184, pp. 111768-111768
Closed Access | Times Cited: 79
A comprehensive overview of β-carbolines and its derivatives as anticancer agents
Bo Luo, Xinqiang Song
European Journal of Medicinal Chemistry (2021) Vol. 224, pp. 113688-113688
Closed Access | Times Cited: 57
Antiviral PROTACs: Opportunity borne with challenge
Jinsen Liang, Yihe Wu, Ke Lan, et al.
Cell Insight (2023) Vol. 2, Iss. 3, pp. 100092-100092
Open Access | Times Cited: 32
Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights
Ahmed Sabt, Wagdy M. Eldehna, Tarfah Al‐Warhi, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2020) Vol. 35, Iss. 1, pp. 1616-1630
Open Access | Times Cited: 66
Synthesis, Biological Evaluation and In Silico Studies of Certain Oxindole–Indole Conjugates as Anticancer CDK Inhibitors
Tarfah Al‐Warhi, Ahmed M. El Kerdawy, Nada Aljaeed, et al.
Molecules (2020) Vol. 25, Iss. 9, pp. 2031-2031
Open Access | Times Cited: 53
A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents
Brilliant N. Marak, Jayanta Dowarah, Laldingluaia Khiangte, et al.
European Journal of Medicinal Chemistry (2020) Vol. 203, pp. 112571-112571
Closed Access | Times Cited: 41
Recent progress of research on anti‐tumor agents using benzimidazole as the structure unit
Kaiyue Wu, Xiaoyu Peng, Miaojia Chen, et al.
Chemical Biology & Drug Design (2022) Vol. 99, Iss. 5, pp. 736-757
Closed Access | Times Cited: 25
Identification of 3-(piperazinylmethyl)benzofuran derivatives as novel type II CDK2 inhibitors: design, synthesis, biological evaluation, and in silico insights
Wagdy M. Eldehna, Raed M. Maklad, Hadia Almahli, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2022) Vol. 37, Iss. 1, pp. 1227-1240
Open Access | Times Cited: 24
Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity
Chunhui Cheng, Yun Fan, Sadeeq Ullah, et al.
European Journal of Medicinal Chemistry (2020) Vol. 189, pp. 112073-112073
Closed Access | Times Cited: 34
Aminopyrimidines: Recent synthetic procedures and anticancer activities
Éclair Venturini Filho, Erick M.C. Pinheiro, Sérgio Pinheiro, et al.
Tetrahedron (2021) Vol. 92, pp. 132256-132256
Closed Access | Times Cited: 32
Analyzing the scaffold diversity of cyclin‐dependent kinase inhibitors and revisiting the clinical and preclinical pipeline
Deendyal Bhurta, Sandip B. Bharate
Medicinal Research Reviews (2021) Vol. 42, Iss. 2, pp. 654-709
Closed Access | Times Cited: 31
Altered pathways and targeted therapy in double hit lymphoma
Yuxin Zhuang, Jinxin Che, Meijuan Wu, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 20
Superenhancers as master gene regulators and novel therapeutic targets in brain tumors
Hai-Hui Zhuang, Qiang Qu, Xin-Qi Teng, et al.
Experimental & Molecular Medicine (2023) Vol. 55, Iss. 2, pp. 290-303
Open Access | Times Cited: 12
Synthesis, in-silico studies, and biological evaluation of some novel 3-thiazolyl-indoles as CDK2–inhibitors
Sobhi M. Gomha, Magdi E. A. Zaki, Deepika Maliwal, et al.
Results in Chemistry (2023) Vol. 6, pp. 101209-101209
Open Access | Times Cited: 12
Synthesis, biological profile and computational insights of new derivatives of benzo [B][1,4] diazepines as prospective anticancer agents for inhibiting the CDK-2 protein
Pervaiz Dar, Basharat Bhat, Mushtaq Ahmad Mir, et al.
Journal of Biomolecular Structure and Dynamics (2024), pp. 1-16
Open Access | Times Cited: 4
Integrated bioinformatics combined with machine learning to analyze shared biomarkers and pathways in psoriasis and cervical squamous cell carcinoma
Luyu Liu, Pan Yin, Ruida Yang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Unraveling a novel therapeutic facet of Etravirine to confront Hepatocellular Carcinoma via disruption of cell cycle
Gouri Nair, G.R. Saraswathy, Jesil Mathew Aranjani, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Exploring β-carboline hybrids and their derivatives: A review on synthesis and anticancer efficiency
Nur Fatihah Sulaiman, Siti Zafirah Zulkifli, Aimi Suhaily Saaidin, et al.
European Journal of Medicinal Chemistry (2025) Vol. 288, pp. 117412-117412
Closed Access
Design and Synthesis of New 5-Methylisatin Derivatives as Potential CDK2 Inhibitors
Przemysław Czeleń, Agnieszka Skotnicka, Beata Szefler, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 2144-2144
Open Access
Synthesis of a New Purine Analogue Class with Antifungal Activity and Improved Potency against Fungal IP3–4K
Desmarini Desmarini, Daniel Truong, Pooja Sethiya, et al.
ACS Infectious Diseases (2025)
Closed Access
Design, synthesis and bio-evaluation of 2,5-disubstituted thiazole derivatives for potential treatment of acute myeloid leukemia through targeting CDK9
Sumeng Chen, Jindi Huang, Shipeng Zhang, et al.
Bioorganic Chemistry (2025), pp. 108436-108436
Closed Access
Pharmacophore-based virtual screening, synthesis, biological evaluation, and molecular docking study of novel pyrrolizines bearing urea/thiourea moieties with potential cytotoxicity and CDK inhibitory activities
Ahmed M. Shawky, Nashwa A. Ibrahim, Mohammed A. S. Abourehab, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2020) Vol. 36, Iss. 1, pp. 15-33
Open Access | Times Cited: 32
Ligand- and structure-based identification of novel CDK9 inhibitors for the potential treatment of leukemia
Huimin Zhang, Jindi Huang, Rui Chen, et al.
Bioorganic & Medicinal Chemistry (2022) Vol. 72, pp. 116994-116994
Closed Access | Times Cited: 18
Page 1 - Next Page

Scroll to top